GoodRx vs MarketAxess

Side-by-side comparison of AI visibility scores, market position, and capabilities

MarketAxess leads in AI visibility (70 vs 28)
GoodRx logo

GoodRx

EmergingHealthcare

Prescription Savings

NASDAQ-listed (GDRX) prescription savings platform comparing prices across 70K+ pharmacies; $750M revenue with stock under pressure from Amazon Pharmacy and Cost Plus Drugs competition.

AI VisibilityBeta
Overall Score
D28
Category Rank
#1 of 1
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
34
Perplexity
27
Gemini
24

About

GoodRx is a Santa Monica-based prescription savings and healthcare price comparison platform that enables consumers to compare prices, access discount coupons, and find the lowest-cost pharmacy for their prescriptions — providing free price comparison tools across 70,000+ US pharmacies and a GoodRx Gold subscription ($9.99/month) with even lower prices on 1,000+ common medications. Listed on NASDAQ (NASDAQ: GDRX), GoodRx went public in September 2020 and generates approximately $750 million in annual revenue primarily from pharmaceutical industry fees and consumer subscription revenue.

Full profile
MarketAxess logo

MarketAxess

LeaderConsumer Finance

Enterprise

New York electronic bond trading (NASDAQ: MKTX) $763M FY2024 revenue; Open Trading $2T+ liquidity, 40% US IG bond electronification, portfolio trading growth competing with Tradeweb and Bloomberg.

AI VisibilityBeta
Overall Score
B70
Category Rank
#13 of 290
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
65
Perplexity
65
Gemini
68

About

MarketAxess Holdings Inc. is a New York City-based electronic fixed income trading platform — publicly traded on the NASDAQ (NASDAQ: MKTX) as an S&P 500 Financials component — operating the leading electronic trading marketplace for US investment-grade corporate bonds, US high-yield bonds, emerging market bonds, municipal bonds, and US Treasury securities through approximately 850 employees globally. In fiscal year 2024, MarketAxess reported revenues of $763 million with record trading volumes in US investment-grade bonds and emerging market credit, as the multi-year electronification trend in bond markets continued to shift institutional fixed income trading from voice broker-dealer phone execution to electronic all-to-all trading on MarketAxess's Open Trading marketplace. CEO Chris Concannon (joined 2023, formerly Cboe Global Markets president) leads MarketAxess's strategy of expanding market share beyond the institutional investment-grade core into rate products (US Treasuries, agency securities), high-yield, and portfolio trading as fixed income electronification accelerates — currently approximately 40% of US investment-grade bonds trade electronically versus 15% in 2015. MarketAxess's Open Trading protocol (anonymous all-to-all price discovery between buy-side, sell-side, and market makers) generated over $2 trillion in liquidity provision in 2024, reducing transaction costs versus bilateral dealer quotes by an average of $0.28 per $100 face value.

Full profile

AI Visibility Head-to-Head

28
Overall Score
70
#1
Category Rank
#13
68
AI Consensus
79
up
Trend
stable
34
ChatGPT
65
27
Perplexity
65
24
Gemini
68
21
Claude
73
31
Grok
65

Key Details

Category
Prescription Savings
Enterprise
Tier
Emerging
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only GoodRx
Prescription Savings
GoodRx is classified as company. MarketAxess is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.